---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-078159"
form_type: "8-K"
ticker: "GLUE"
cik: "0001826457"
company_name: "Monte Rosa Therapeutics, Inc."
filed_at: "2024-06-27T23:59:59+00:00"
generated_at: "2026-06-01T01:07:22.018732+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Monte Rosa: MRT-2359 dose update; MRT-6160 IND for autoimmune diseases

## Summary
- MRT-2359 Phase 1/2: favorable safety at 0.5 mg 21/7 schedule; evaluating 0.75 mg cohort; RP2D and updated data expected H2 2024.
- IND submitted for MRT-6160, VAV1-directed MGD for systemic/neurological autoimmune diseases; Phase 1 SAD/MAD starts summer 2024 with data Q1 2025.
- MRT-2359 potential RP2D of 0.5 mg using 21 days on/7 days off regimen, allowing twice as frequent dosing per cycle vs prior schedule.
- MRT-6160 is first rationally designed MGD for non-oncology indication; preclinical efficacy in IBD, RA, MS models.

## SEC filing metadata
- accession: 0000950170-24-078159
- form_type: 8-K
- ticker: GLUE
- cik: 0001826457
- company_name: Monte Rosa Therapeutics, Inc.
- filed_at: 2024-06-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826457/000095017024078159/0000950170-24-078159-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826457/000095017024078159/glue-20240627.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-078159
- JSON: https://secwatch.observer/filing/0000950170-24-078159.json
- Plain text: https://secwatch.observer/filing/0000950170-24-078159.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.